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The present study examined the overloading of ion-
exchange membrane adsorbers, a form of frontal
chromatography, as the ﬁnal puriﬁcation step in the
production of mAbs (monoclonal antibodies) produced
from CHO (Chinese-hamster ovary) cells. Preferential
binding of impurities over antibody product was
exploited using commercially available cation- and
anion-exchange membranes. Three different antibody
feedstreams previously puriﬁed over Protein A and
ion-exchange column chromatography were tested.
Feedstream conductivity and pH were adjusted to
induce product and impurity adsorption. Membranes
were then overloaded in a normal ﬂow mode,
resulting in retention of impurities and breakthrough
of puriﬁed antibody. Although some amount of the
product also binds to the membranes (usually 30 g
mAb/l membrane), yields of 99% were achieved by
marginalizing the losses, typically by loading more than
3 kg mAb/l membrane. Analyses of the puriﬁed pools
show consistent removal of impurities despite strong
mAb–ligand interactions and high membrane loadings.
The clearance of host cell proteins was affected by
pH and conductivity, but was unaffected by ﬂow rate,
membrane properties or scale. The importance of
the present study lies in our demonstration of an
alternative use of ion-exchange membranes for fast,
effective and high yielding puriﬁcation of mAbs.
Introduction
The advantages of membrane chromatography over
traditional column-based separations are well established.
Column chromatography methods are robust and reliable
but generally have low throughput due to pore diffusion
limitations within the resin beads. Membranes have shorter
diffusion times and therefore separation efﬁciencies can
be maintained at high ﬂow rates [1–5]. Membranes are
also more convenient because they do not require column
hardware or packing [6], they reduce buffer usage and
ﬂoor space requirements and they generally improve
manufacturing ﬂexibility [7].
Despite having many advantages, membrane chromato-
graphy did not acquire the success anticipated almost two
decades ago. The inability of membrane chromatography
to gain industrial acceptance has been attributed to the
reticence among users in applying new technologies [8].
Technical, operational and regulatory implications of new
technologies and the investment in existing equipment
have also been described as chief barriers to change [9].
Additionally, membranes are expensive and their binding
capacities for mAbs (monoclonal antibodies) are relatively
low compared with modern resins. Consequently, their
breadthofuseislimitedbecausetheyarenotagoodmedium
forperformingindustrial-scaleelutionchromatography(bind
and elute chromatography) [10].
However, the views on the use of membranes for
mAb downstream processing may be changing as the
biopharmaceutical industry has been evolving. Zhou and
Tressel [11] reviewed the ﬁndings of multiple researchers
who have shown that anion-exchange membranes operated
in ﬂow-through mode are effective downstream of Protein
A puriﬁcation. Membranes are ideal in this ‘polishing’
position, because they have a distinct ﬂow rate advantage
and sufﬁcient capacity within a relatively small footprint
for binding trace impurities and contaminants [6,12,13].
Additionally, advancements in process knowledge and
improved Protein A resins are raising the acceptance level
for membrane usage by decreasing the amount of impurities
passed downstream, and there is also an increasingly tangible
need for high-throughput technologies that can handle
bigger batches. Bioreactor titres for mAbs are increasing [9]
and batches greater than 100 kg may be difﬁcult to purify
using traditional column chromatography [14]. Membrane
usage is likely to increase in the future as drug producers
seek greater speed and efﬁciency and effective cost of goods.
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Table 1 Summary of feedstream characteristics
Product Upstream process Nomenclature pH Conductivity (mS/cm) Concentration (g/l) IgG type pI
a
mAb 1 Protein A followed by ﬂow-through anion exchange
b Anion exchange pool 5.5 6.0 4.8 1 8.9
Protein A
b Protein A pool 5.5 4.4 5.9 1
mAb 2 Protein A followed by ﬂow-through anion exchange Anion-exchange pool 8.0 5.0 5.4 1 9.3
mAb 3 Protein A followed by bind and elute cation exchange Cation-exchange pool 5.5 9.0 4.1 1 7.7
aCalculated pI based on the amino acid sequence.
bPool pH and conductivity have been previously adjusted to ensure adequate product stability.
One application of membranes that has received little
attention from mAb puriﬁcation researchers is frontal
chromatography [15], where the mobile phase conditions
(load conditions) promote both impurity and product
adsorption. For clarity, henceforth we call this technique
overload chromatography, so as not to be confused with
another form of frontal chromatography where the product
does not bind, called ﬂow-through chromatography. These
terms are informal and are deﬁned here for discussion
purposes only.
Overload chromatography exploits the differential
binding between the product and impurities. In the examples
studied in the present paper, the impurities appear to bind
stronger than the product to ion-exchange membranes,
adsorbing tightly while the product desorbs and ﬂows into
the membrane efﬂuent. Because some antibody stays bound
to the membranes, the economic viability of the step hinges
on the collection of a disproportionately large amount of
the product in the membrane efﬂuent.
The inherent yield loss associated with this approach
may be one of the reasons why it has not been
seriously studied by mAb puriﬁcation researchers until
now. Historically, ﬂow-through chromatography has been
preferred for its high yield and generally straightforward
operation, and these beneﬁts were believed to end at the
operating limits where the product begins to bind. However,
this is not always the case, and theoretically, operating under
conditions where the product and impurities compete may
be advantageous.
In the present study, we investigate overload
chromatography for the unique circumstances encountered
in mAb downstream processing. The platform use of
ProteinAfollowedbyion-exchangecolumnchromatography
produces a relatively consistent set of conditions that
includes large-volume pools with only trace impurities. Such
conditions are ideal for using membranes as the third
and ﬁnal polishing step, whether it be in ﬂow-through or
overload mode. However, it is only the overload mode that
is uniquely advantageous to membranes, as the large pool
volumes and potential for appreciable yield loss discourage
the use of traditional packed resin beds. A more detailed
explanation for this is provided in the Results and discussion
section.
Applying overload chromatography to the puriﬁcation
of Genentech mAb feedstreams, we observed that
impurities that are commonly present downstream of
Protein A bind to ion-exchange membranes despite the
presence of strong mAb–ligand interactions. Our evidence
suggests that it is possible to leverage this phenomenon to
purify antibodies, and we believe that it can be an effective
and potentially economical means of puriﬁcation.
In the present study, overload chromatography on
ion-exchange membrane adsorbers was examined as the
ﬁnal polishing step for mAb puriﬁcation. Three different
feedstreams produced at Genentech, previously processed
over Protein A and ion-exchange column chromatography,
were tested using commercially available cation- and anion-
exchange membranes. Our analysis begins with mAb 1
where we demonstrate proof of concept. It then expands
to include mAbs 2 and 3, where we investigate the impact
of pH and conductivity on cation- and anion-exchange
membranes. We then return to mAb 1 and use it as a model
(i) to explore the differences between cation-exchange
membranes produced by two commercial vendors, (ii) to
evaluate the effect of ﬂow rate and the impact of scale and
(iii) to study the mechanism of impurity removal.
Materials and methods
Feedstock
Feedstocks were selected from industrial, pilot or small-
scalecellculturebatchesatGenentech(SouthSanFrancisco,
CA, U.S.A.), and each was partially puriﬁed, meaning that
the cells were separated and the clariﬁed ﬂuid was puriﬁed
over Protein A followed by ion-exchange chromatography
(Table 1). Multiple batches of mAb 1 were used, resulting in
small differences in CHOP [CHO (Chinese-hamster ovary)
protein] levels. These differences are likely a result of assay
variability and possibly lot differences. The Protein A pool
wasusedtoinvestigatethemechanismofimpurityclearance.
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Table 1 shows feedstock characteristics for each mAb used
in the present study.
mAb quantiﬁcation
The concentration of antibody was determined via
absorbance (A) at 280 and 320 nm using a UV–
visible spectrophotometer (8453 model G1103A; Agilent
Technologies; Santa Clara, CA, U.S.A.) or NanoDrop 1000
model ND-1000 (Thermo Fisher Scientiﬁc; Waltham, MA,
U.S.A.). Species other than antibody (i.e. impurities) were
too low in concentration to have an appreciable effect on
UV absorbance. As needed, samples were diluted with an
appropriate non-interfering diluent in the range of 0.1–1.0
absorbance unit. Sample preparation and UV measurements
were performed in duplicate and the average value was
recorded. The mAb absorption coefﬁcients ranged from




CHO host cell protein (CHOP) quantiﬁcation
An ELISA was used to quantify the levels of the host
cell protein called CHOP. Anti-CHOP antibodies were
immobilized on microtitre plate wells. Dilutions of the
samples containing CHOP, standards and controls were
incubated in the wells, followed by incubation with
anti-CHOP antibodies conjugated with HRP (horseradish
peroxidase). The HRP enzymatic activity was detected
with o-phenylenediamine, and the CHOP was quantiﬁed
by reading absorbance at 490 nm in a microtitre plate
reader. Based on the principles of sandwich ELISA,
the concentration of peroxidase corresponded to the
CHOP concentration. The assay range for the ELISA
was typically 10–320 ng/ml with intra-assay variability 
10%. CHOP values were reported in units of ng/ml.
Alternatively, they were divided by the mAb concentration
and the results were reported in units of PPM (parts
per million; ng of CHOP/mg of mAb). The CHOP
ELISA is a generic assay capable of quantifying total
CHOP levels but not the concentration of individual
proteins.
Filtrate samples exhibiting CHOP levels below the
LOQ (limit of quantiﬁcation) were concentrated in an effort
to obtain quantiﬁable results. Samples were concentrated
approx. 10-fold using an Amicon® Ultra-15 centrifugal
10 kDa NMWCO (nominal molecular-mass cut-off) ﬁlter
produced by Millipore (Billerica, MA, U.S.A.) centrifuged
on an Eppendorf 5810R centrifuge (Eppendorf, Hamburg,
Germany) at 5–25◦C and 3000–4700 g for 10–20 min.
Gentamicin quantiﬁcation
Gentamicin levels were determined using a competition
ELISA. A polyclonal antibody directed to gentamicin and
a second synthesized form of gentamicin was immobilized
on microtitre plate wells. Gentamicin competes with
the synthesized form for binding to the antibody. The
amount of bound synthesized gentamicin was detected using
HRP–streptavidin and o-phenylenediamine dihydrochloride
substrate. Gentamicin was detected by reading the
absorbance at 490 nm in a microtitre plate reader. The assay
range for the ELISA was typically 3–90 ng/ml. Gentamicin
values were reported in units of ng/ml. Alternatively, they
were divided by the mAb concentration and the results are
reported in units of PPM (ng of gentamicin/mg of mAb).
SEC (size-exclusion chromatography)
A TSK G3000SWXL SEC column (diameter=7.8 mm,
height=300 mm; part number 08541) manufactured by
Tosoh Bioscience (Tokyo, Japan) was operated at ambient
temperature (approx. 25◦C) on a 1200 series HPLC
instrument (Agilent Technologies) and used to determine
the relative levels of mAb monomer for the collected
samples. Each sample was diluted to approx. 0.5 g/l antibody
using a mobile phase containing a 200 mM potassium
phosphate/250 mM potassium chloride buffer at pH 6.2.
Runs were 30 min with a 0.5 ml/min ﬂow rate and 50 μl
injections. If protein concentrations were near 0.5 g/l in
the initial samples, no dilution was performed prior to
operation. Additionally, if the initial concentration was
0.25 g/l, then a 100 μli n j e c t i o nw a su s e dt ot r yt o
normalize for the mass loaded on to the column. UV 280 nm
absorbance was recorded and peaks were analysed manually
using ChemStation software (Agilent Technologies).
Membranes
Membranes Mustang® S and Q and Sartobind® Sw e r e
purchased from Pall Corporation (East Hills, NY, U.S.A.)
and Sartorius-Stedim (Aubagne, France) respectively. MV
(membrane volume) is the total physical volume of the
membrane (solids and voids) and is reported in units of
millilitres or litres. Table 2 lists the relevant information for
each membrane used in the present study.
Filtration systems
Small- and pilot-scale tests were performed using an AKTA
Explorer 100 or AKTA Pilot (GE Healthcare, Fairﬁeld,
CT, U.S.A.). Small-scale tests were also performed using
a manual system consisting of a Masterﬂex® L/S® digital
economy drive peristaltic pump (Cole Parmer, Vernon Hills,
IL, U.S.A.), in-line DTX
TM Plus TNF-R pressure sensor
(Becton Dickinson, Franklin Lakes, NJ, U.S.A.) and an AND
EK-1200ibalance(A&D,Tokyo,Japan).Thebalancewasused
to monitor the ﬂow rate of the pump by measuring the mass
accumulation. Mass was converted to volume assuming a
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Table 2 Summary of membrane characteristics
Membrane Device Part number Membrane thickness (cm) Layers number MV (ml) Pore diameter (μm)
Mustang® S2 5 m m A c r o d i s c ® MSTG25S6 0.01375 6 0.18 0.8
Mustang® S Capsule CLM05MSTGSP1 0.01375 16 10 0.8
Sartobind® S 25 mm MA5 S5F 0.0275 1 0.14 3–5
Mustang® Q Coin MSTG18Q16 0.01375 16 0.35 0.8
feedstream density of 1.0 g/ml. Pressure from the in-line
transducers and mass from the balance were continuously
monitored using a NetDAQ
TM 2640A/41A network data
acquisition system (Fluke, Everett, WA, U.S.A.), which was
linked to a computer running the software Trendlink
TM
version 3.1.1 (Canary Labs, Martinsburg, PA, U.S.A.) and
RsCom version 2.40 (A&D).
Experimental
Feedstocks were removed from cold storage (2–8◦Co r
–70◦C) and allowed to equilibrate to room temperature
(approx. 22◦C). Subsequently, they were pH and/or
conductivity adjusted as necessary from the conditions
shown in Table 1 using a titrating agent (1.5 M Tris base
or 1 M citric acid) or diluent (puriﬁed water or 5 M sodium
chloride). To minimize adsorber fouling, all feedstocks were
0.2 μm ﬁltered as a precautionary measure using a Millipak-
20 (Millipore), AcroPak
TM 20 (Pall Corporation) or 1000 ml
vacuum ﬁlter (Thermo Fisher Scientiﬁc, Rochester, NY,
U.S.A.).
The ﬁltration system was rinsed with puriﬁed water
or a buffer (typically 20 mM acetate, pH 5.5) and then the
membrane was placed in-line and ﬂushed with 50–500 MV
of puriﬁed water or equilibration buffer (20 mM acetate,
pH 5.5). Feed was directed to the membrane at a constant
ﬂow rate of 333–2667 MV/h until the target amount of
antibody was loaded and then the membrane was washed
with a buffer to remove any unbound species. The wash
buffer was selected to maintain retention of the mAb and
impurities and was thus similar in pH as the feed but was
lower in conductivity than the feed. For testing the effects
of scale, the wash and equilibration buffers were puriﬁed
water and the membrane adsorber was eluted into a high-
salt buffer (20 mM acetate and 350 mM sodium chloride,
pH 5.5, or 25 mM Tris and 250 mM sodium chloride, pH 8.0)
at a similar ﬂow rate to the load and wash phases.
Results and discussion
Overloading membranes in mAb downstream
processing
For mAb puriﬁcation, a unique aspect of overload
chromatography is that it does not lend itself to being
efﬁciently performed on traditional packed resin beds.
This is because of the conditions typically encountered
downstream of Protein A. Most commercial mAb processes
start with Protein A and are followed by ion-exchange
column chromatography, resulting in large pools with
trace impurities. To further purify a pool like this using
an overloaded column, the ideal dimensions would be
very thin and wide to accommodate short process times
(high ﬂow rates) with minimal binding capacity required.
This conﬁguration is impractical due to a variety of
ﬂow distribution and column packing limitations. Flow
distribution issues require operating a smaller diameter
column with increased bed height. Again, in overload mode,
the column is operated under conditions where the mAb
can bind to the resin; thus increasing the bed height
will reduce the yield and increase the ﬂow resistance. To
overcome these obstacles requires operating small columns
at longer process times (low ﬂow rates). By comparison,
membranes offer a unique opportunity. A small membrane
is capable of avoiding the ﬂow distribution and resistance
issues encountered with a column, while allowing for ample
removal of trace impurities, minimal loss of product and
short process times.
Before proceeding, it should be noted that overload
chromatography has been studied for many years on
columns [16–19], and it is also worth noting that if the
nature of the multilateral binding were reversed, causing
antibody to bind tighter than impurities, then packed bed
resins would be favoured over membranes because of their
superior binding capacity and lower costs.
Proof of concept
Figure 1 shows the antibody, CHOP and gentamicin
breakthrough curves for mAb 1 anion-exchange pool on
a small-scale Mustang® S membrane at pH 5.5 and at
a conductivity of 6.0 mS/cm. As shown in Table 1, this
feedstock was previously processed over Protein A followed
by ﬂow-through anion-exchange column chromatography.
In the load conditions described, mAb 1 with a pI of 8.9
is positively charged and readily binds to the negatively
charged membrane along with CHOP and gentamicin.
Loading beyond the point of mAb breakthrough (where
C/Co is approx. 1) revealed greater than 80% of the CHOP
and 90% of the gentamicin bound to the membrane, as
evidenced by C/Co values substantially less than 1. The
C   2010 Portland Press Limited
© 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.Overloading membrane adsorbers 63
Figure 1 Breakthrough curves for mAb 1, CHOP and gentamicin over cation-exchange membrane Mustang® S
C/Co is the ratio of CHOP, gentamicin or mAb in the membrane efﬂuent to that in the feed. The mAb 1 (pI 8.9) anion-exchange pool at pH 5.5 and 6.0 mS/cm was
loaded on to 16 kg mAb/l membrane (2.2 kg mAb/m
2 membrane) over a small-scale Acrodisc® membrane (six-layer device, 0.18 ml MV) at 667 MV/h (55 cm/h).
The feed concentrations for mAb, CHOP and gentamicin were 4.8 mg/ml, 181 ng/ml (38 PPM) and 34 ng/ml (7.1 PPM) respectively.
respective levels of CHOP and gentamicin were reduced
from 38 and 7 PPM in the feed to 5.7 and 0.5 PPM by the end
of the experiment at approx. 16 kg mAb/l membrane. The
results of this experiment show that trace levels of CHOP
and gentamicin can bind to a cation-exchange membrane in
the presence of a relatively high concentration of positively
charged mAb.
Although not depicted in Figure 1, our experience
with IgG adsorption on Mustang® S has shown a binding
capacity upper limit of approx. 30 g mAb/l membrane, which
when loaded to 16 kg mAb/l membrane translates to a
minimum theoretical yield of approx. 99.8%. The yield for
thisexperimentwasmeasuredatapprox.100%afterloading
only 5 kg mAb/l membrane. These ﬁndings are consistent
with theory and illustrate how product losses can be
marginalized by extensive overloading. For some readers, it
may be desirable to establish a minimum membrane loading
based on an acceptable low limit for yield. We believe the
binding capacity is a good starting point for this analysis, as
it appears to be consistent between small and pilot scales;
however, it should be noted that it is likely to be dependent
on the speciﬁc antibody, the type and brand of ion-
exchange membrane and the solution pH and conductivity.
Therefore minimum loadings should be established using
experimentally determined binding capacities.
Although the mechanism of adsorption has not been
elucidated, a likely explanation for the fractional binding
in Figure 1 is that the heterogeneous CHOP population
has subpopulations that bind to the membrane tightly,
and other subpopulations with limited to no binding.
This feedstream was processed through Protein A and
anion-exchange ﬂow-through column chromatography and
therefore the remaining CHOP would tend to be more
basic and thus prone to strong binding on a CEX (cation
exchange) membrane in the conditions tested. However,
given the heterogeneity of the CHOP, it would be difﬁcult
to remove all in a single step or even multiple steps,
because each operating condition results in different binding
strengths. Therefore one might always expect some degree
of multilateral binding, breakthrough and leaking proﬁles
depending on the operating conditions. Gentamicin also
contains a heterogeneous population of components [20–
22], but far less so than CHOP, and at the pH tested, all
isomers should be positively charged and thus bind to the
membrane. Additional research is necessary in order to
better explain the observed behaviour.
Impact of pH and conductivity
The mAb 2 source material at pH 8.0 and 5.0 mS/cm
(Table 1) was split into two separate pools; the ﬁrst pool
was not adjusted and the second was titrated to pH 5.5
and 6.4 mS/cm using 1 M citric acid. Figure 2 shows the
antibody and CHOP breakthrough curves for both pools
processed over a small-scale Mustang® S cation-exchange
membrane. For the two different pH conditions, similar
C   2010 Portland Press Limited
© 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.64 A. Brown and others
Figure 2 Breakthrough curves for CHOP and mAb 2 over the cation-exchange membrane Mustang® S at pH 8.0 and 5.5
C/Co is the ratio of CHOP or mAb in the membrane efﬂuent to that in the feed. The mAb 2 (pI 9.3) anion-exchange pool was split into two separate pools:
the ﬁrst pool was maintained at the initial conditions of pH 8.0 and 5.0 mS/cm and the second pool was pH adjusted to 5.5 and 6.4 mS/cm using 1 M citric acid.
Both pools were loaded on to approx. 6.5 kg mAb/l membrane (0.89 kg mAb/m
2 membrane) over a small-scale Acrodisc® cation-exchange membrane (six-layer
device, 0.18 ml MV) at 667 MV/h (55 cm/h). The feed concentration of mAb 2 was 5.4 mg/ml and the concentration of CHOP was 314 and 274 ng/ml (58 and
51 PPM) at pH 8.0 and 5.5 respectively.
yield (measured at >96%) and antibody breakthrough
were observed. However, the CHOP breakthrough was
very different, indicating pH dependence consistent with
electrostatic adsorption. The difference in CHOP binding
is possibly due to an increase in net charge caused by the
changeinpHfrom8.0to5.5.Suchresultswouldbeexpected
given the upstream process. Similar to mAb 1, the mAb
2 feedstream was previously processed through Protein A
and anion-exchange ﬂow-through column chromatography,
which should have produced a more basic CHOP
population that binds more tightly to a CEX membrane at
low pH.
Conductivity dependencies on an anion-exchange
membrane are shown in Figure 3. mAb 3 was selected
because its lower pI (pI 7.7) facilitated operation at a pH
above the pI without signiﬁcant risk of product degradation.
The primary y-axis shows the pool CHOP levels in PPM
after loading mAb 3 cation-exchange pool to 1 kg mAb/l
membrane over a small-scale Mustang® Q at pH 8.0 and
conductivities 4, 7 and 10 mS/cm. Overlaid with these data
on the secondary y-axis are the corresponding mAb 3
binding capacities determined after loading to 1 kg mAb/l
membrane (>100% breakthrough). The results show an
increase in pool CHOP from <0.6 PPM (<LOQ) at 4 mS/cm
to4.7PPMat10mS/cm.Atthesametime,themAb3binding
capacity decreased by 42% from approx. 18 to 11 g mAb/l
membrane. Binding of CHOP appears to decrease with
increasing conductivity, which is consistent with previous
observations made for anion-exchange membranes used in
ﬂow-through mode [7]. Despite the decrease in puriﬁcation,
the anion-exchange membrane does an impressive job,
reducing CHOP at least 38-fold from the feedstream value
of approx. 180 PPM. This reduction is signiﬁcantly higher
than for the previous studies using an anion-exchange
ﬂow-through pool run over a cation-exchange membrane
(approx. 5- and 13-fold for mAb 1 and mAb 2 respectively).
The exact reason for the enhanced separation is not known
but it could be due to the nature of the feedstock and
the upstream process (Table 1). It has been reported
in the literature that around neutral pH and at low
conductivity, a large percentage of CHO host cell proteins
are negatively charged [11]. It would appear that many
of these acidic species bound to the upstream cation-
exchange column and were co-eluted with the antibody at
pH 5.5.
Reviewing the results from Figures 1–3, it is clear
that this approach is not mAb dependent and can be
performed reasonably well on both cation- and anion-
exchange membranes. It is also clear that impurity and
mAb binding are based on electrostatic adsorption and
are therefore subject to the factors that affect charge
interactions including pH and conductivity.
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Figure 3 Effect of conductivity on CHOP clearance and mAb 3 binding capacity for the anion-exchange membrane Mustang® Q
CHOP concentration (shown by bars) is plotted on the primary y-axis and mAb 3 binding capacity (solid triangles) is plotted on the secondary y-axis. The mAb 3
(pI 7.3) cation-exchange pool at pH 5.5 and 9 mS/cm was pH adjusted to 8.0 using 1.5 M Tris base. The feedstock was then split into three separate pools and
the conductivity was adjusted using puriﬁed water. Each pool was processed over a small-scale Coin anion-exchange membrane (16-layer device, 0.35 mlM V )a t
600 MV/h (131 cm/h) to 1 kg mAb/l membrane (0.14 kg mAb/m
2 membrane). The respective mAb and CHOP feed concentrations at 4, 7 and 10 mS/cm were
1.6, 3.0 and 4.2 mg/ml for mAb 3 and 280, 530 and 740 ng/ml (approx. 180 PPM) for CHOP. CHOP levels in the pool at 4 mS/cm were below the LOQ despite
a greater than 10 times concentration on an Amicon® UF device. The LOQ of the CHOP assay was 10 ng/ml.
Brand comparison
Figure 4 shows the mAb 1 and CHOP breakthrough curves
for the Sartobind® S overlaid with the previous set of
Mustang® S data shown in Figure 1. For the Sartobind® S,
the batch of mAb 1 anion-exchange pool contained slightly
l o w e rl e v e l so fC H O P ,b u tw a sp r o c e s s e do v e rt h es m a l l -
scale membrane at the same pH and conductivity as the
previous experiment (pH 5.5 and 6 mS/cm). The Sartobind®
S reduced CHOP from 29 PPM in the feed to an initial
value of 3.3 PPM at 1.8 kg mAb/l membrane, and by the
end of the experiment at 11.5 kg mAb/l membrane, the
levels increased slightly to 5.6 PPM. Although the CHOP
appears to break through slightly faster for the Sartobind®
S, we suspect this may be attributed to the fact that there
is only a single membrane layer inside the MA5 device.
Alternatively, it could also be explained by a difference
in CHOP caused by feedstock variability. A repeat test
comparing the devices on the same feedstock using a more
representative, multi-layer Sartobind device is necessary
before any signiﬁcant distinctions can be made. At a
minimum, the data demonstrate reasonable agreement in
CHOP clearance between the Sartobind® and Mustang®
S membranes. More importantly for biopharmaceutical
manufacturers, this approach does not appear to be speciﬁc
to a single membrane supplier.
Effect of ﬂow rate
To test the effect of ﬂow rate on CHOP breakthrough, the
Mustang® S was studied over a broad range of conditions.
Previous publications have shown that ﬂow rate has little
to no effect on membrane separations [2–5,10], but it
was not immediately clear whether this would hold true
in this case. To ascertain the effect of ﬂow rate, mAb 1
anion-exchange pool at pH 5.5 and 6 mS/cm was processed
over small-scale Mustang® S membranes at 333, 667, 1333
and 2667 MV/h (27, 55, 110 and 220 cm/h). The mAb
1 and CHOP breakthrough curves at each ﬂow rate are
overlaid in Figure 5. The Mustang® S initially reduced CHOP
from 45 to approx. 6.9 PPM, increasing to an average of
approx. 8.7 PPM by 16 kg mAb/l membrane. The mAb and
CHOP breakthrough curves are similar, indicating that like
other types of membrane separations, the performance of
overload chromatography is independent of ﬂow rate.
Impact of scale
To determine the impact of scale, a larger Mustang® S
membrane representing a 56-fold increase in scale was
tested using mAb 1 and compared with previous results. The
pilot-scale device was 10 ml and had 16 layers of membrane
comparedwith0.18 mland6layersatsmallscale.Aseparate
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Figure 4 Breakthrough curves for CHOP and mAb 1 over the cation-exchange membranes Mustang® S and Sartobind® S
C/Co is the ratio of CHOP or mAb in the membrane efﬂuent to that in the feed. The mAb 1 (pI 8.9) anion-exchange pool at pH 5.5 and 6.0 mS/cm was
loaded on to approx. 11.5 kg mAb/l membrane (3.16 kg mAb/m
2 membrane) over a small-scale Sartobind® S MA5 (one-layer device, 0.14 ml MV) at 857 MV/h
(24 cm/h). The results are overlaid with the small-scale Mustang® SA c r o d i s c ® data shown previously in Figure 1. The feed concentrations for mAb and CHOP
were 4.8 mg/ml and 181 ng/ml (38 PPM) for the Mustang® S and 4.9 mg/ml and 143 ng/ml (29 PPM) for Sartobind® S.
Figure 5 Breakthrough curves for CHOP and mAb 1 at ﬂow rates 333, 667, 1333 and 2667 MV/h over cation-exchange membrane Mustang® S
C/Co is the ratio of CHOP or mAb in the membrane efﬂuent to that in the feed. The mAb 1 (pI 8.9) anion-exchange pool at pH 5.5 and 6.0 mS/cm was loaded
on to 16 kg mAb/l membrane (2.2 kg mAb/m
2 membrane) over small-scale Acrodisc® membranes (six-layer device, 0.18 ml MV) at ﬂow rates ranging from 333
to 2667 MV/h (27–220 cm/h). The feed concentrations for mAb and CHOP were 4.7 mg/ml and 211 ng/ml (45 PPM) respectively.
batch of mAb 1 anion-exchange pool at pH 5.5 and 6 mS/cm
was used for the present study. After the load phase, the
membrane was washed and eluted. Figure 6 shows the mAb
1 and CHOP breakthrough curves overlaid with previous
small-scale Mustang® S data shown in Figure 1. The CHOP
breakthrough at pilot scale shows excellent agreement with
small scale. The 10 ml pilot-scale device reduced CHOP
from 42 PPM in the feed to a ﬁnal value of 4.9 PPM at
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Figure 6 Effect of scale on CHOP and mAb 1 breakthrough for the cation-exchange membrane Mustang® S
C/Co is the ratio of CHOP or mAb in the membrane efﬂuent to that in the feed. The mAb 1 (pI 8.9) anion-exchange pool at pH 5.5 and 6.0 mS/cm was loaded
to 7 kg mAb/l membrane over the pilot-scale Mustang® S capsule (16-layer device, 10 ml MV) at 555 MV/h (124 cm/h). The pilot-scale results are overlaid with
the small-scale Mustang® SA c r o d i s c ® data shown previously in Figure 1. The feed concentration of mAb 1 was 4.7 mg/ml and the concentration of CHOP was
194 ng/ml (41 PPM).
7 kg mAb/l membrane. These results are similar to small
scale (Figure 1), where the Acrodisc® reduced CHOP from
38 PPM in the feed to 5.3 PPM at approx. 8 kg mAb/l
membrane.
Analysis performed on the high-salt membrane elution
showed a substantial enrichment of CHOP (results not
shown), which supports the conclusions drawn from
Figures 2 and 3 that impurities bind to the membrane due to
electrostatic forces. Additionally, the yield was 98%, which
closely matches the previous small-scale result of approx.
100%. We consider the pilot device as representative
of industrial scale because the number of membrane
layers, pleating and device assembly are similar to much
larger cartridges and capsules that could be used for
mAb production. Based on these ﬁndings, it appears that
scaled-down ﬂat sheet membrane devices are capable
of predicting the performance of much larger pleated
devices.
To reduce costs, it may be desirable to reuse the
membranes. Our experience suggests limited reuse may be
possible, as the pilot-scale experiment shown in Figure 6
was repeated a second time on the same membrane
with similar results obtained. However, we also have
evidence that suggests that cleaning membranes loaded
to high throughputs may be problematic, necessitating
the use of aggressive regeneration solutions such as 6 M
guanidinium chloride. These ﬁndings are preliminary and
a more thorough evaluation is needed to determine the
feasibility and value of membrane reuse.
Preliminary evidence for the mechanism of
impurity removal
Although the mechanism of impurity removal is not known,
our leading hypothesis is competitive binding. To test this
hypothesis, an experiment was performed using mAb 1
Protein A pool at pH 5.5 and 4.4 mS/cm. In general, the
approach used was similar to that employed by Veeraragavan
et al. [18] in their analysis of overload chromatography with
ovalbumin on a packed anion-exchange column.
Four small-scale Mustang® S membrane devices were
loaded with mAb 1 to different levels (1, 5, 10 and 15 kg
mAb/l membrane) and then chased with a buffer to a UV
baselineofzero.Themembraneswerethenelutedinalinear
gradientfrom0to100%buffered2 Msodiumchloride.Grab
samples were collected during overloading and fractions
were collected during the gradient and measured ofﬂine
for total protein concentration, CHOP, gentamicin and SEC.
The Protein A pool was used as the feedstream
because it contained a 10-fold higher CHOP concentration
compared with the previously used anion-exchange pool.
Using the Protein A pool introduced some uncertainty with
respect to impurity binding because of the more diverse
CHOP population, but the higher levels were viewed as
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Figure 7 mAb 1, CHOP and gentamicin breakthrough curves for Protein A pool
C/Co is the ratio of mAb 1, CHOP or gentamicin in the membrane efﬂuent to that in the feed. The mAb 1 (pI 8.9) Protein A pool at pH 5.5 and 4.4 mS/cm was
loaded on to approx. 15 kg mAb/l membrane (2.1 kg mAb/m
2 membrane) over a small-scale Mustang® SA c r o d i s c ® membrane (six-layer device, 0.18 ml MV) at
1333 MV/h (110 cm/h). The feed concentrations for mAb, CHOP and gentamicin were 5.9 mg/ml, 2400 ng/ml (410 PPM) and 41 ng/ml (6.9 PPM) respectively.
advantageous because the feedstream was more aggressive
and in theory could help to reduce the antibody load-
ing and amplify any puriﬁcation effects. Changes to antibody
and gentamicin binding were not expected because of
the similarities in concentration and solution conditions
between the two pools.
Figure 7 shows the breakthrough curves for antibody,
CHOP and gentamicin taken from the highest mAb loading
conditions (15 kg mAb/l membrane). These data reﬂect the
grab samples taken from the membrane efﬂuent during
the overload phase of the experiment. The breakthrough
of antibody and gentamicin is similar to results previously
reported in Figure 1, while the breakthrough of CHOP
shows signs of increased multilateral binding and leaking.
These results are consistent with expectations and likely
reﬂect increased levels of acidic CHOP. Again, the anion-
exchange ﬂow-through column is responsible for the
removal of acidic species. Without the aid of this upstream
step, the load would be expected to contain more host
cell proteins that have trouble binding to a cation-exchange
membrane in the conditions tested. Although the CHOP
population is more diverse than the anion-exchange pool,
fundamentally this should not be a problem for testing
our hypothesis because most of the impurities bind to the
membrane. Overall, it appears that the Protein A pool
is an acceptable, more aggressive model for testing our
hypothesis.
Figure 8 shows the mass of mAb monomer, CHOP
and gentamicin in each of the gradient elution fractions. The
relative position of the peak maxima shows that monomers
elute ﬁrst, followed by CHOP and then gentamicin. Because
the gradient moves from low to high salt concentration,
the position in the gradient elution provides some insight
into the strength of binding. The results suggest that
gentamicin binds stronger than CHOP, which binds stronger
than monomers. Additionally, as mAb loading increased
from 1 to 15 kg mAb/l membrane, the levels of monomer
decreased, while CHOP and gentamicin increased. One
possible explanation for this behaviour is that CHOP and
gentamicin displace monomers on the membrane surface.
For gentamicin, there are some published data that
suggest that this species may have strong adsorbtive
properties. Kundu et al. [23] showed that it is possible
to displace large, tightly bound proteins from a cation-
exchange column using the low-molecular-mass antibiotics
neomycin B and streptomycin A. Like the displacers used by
Kundu et al. [23], gentamicin is an aminoglycoside antibiotic
[20,21] with a large net positive charge and thus would be
expected to bind tightly to a cation-exchange membrane at
the conditions tested.
A study of adsorption kinetics and generation of single-
and multi-component adsorption isotherms is necessary
to know for sure whether the observations are due to
competitive binding.
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Figure 8 Mass of immobilized mAb 1 monomer, CHOP and gentamicin
collected in each fraction during gradient elution of the Mustang® S
membrane after loading 1, 5, 10 and 15 kg mAb/l membrane (0.14, 0.69,
1.4 and 2.1 kg mAb/m
2 membrane)
The mAb 1 (pI 8.9) Protein A pool at pH 5.5 and 4.4 mS/cm was processed
over small-scale Mustang® SA c r o d i s c ® membranes (six-layer device, 0.18 ml
MV) at 1333 MV/h (110 cm/h), washed using 20 mM acetate (pH 5.5) and
then eluted in a linear gradient from 0 to 100% into 2 M NaCl and 20 mM
acetate (pH 5.1) over 20 ml. Gradient fractions were collected every 2 ml
and pooling was initiated based on volume. The ﬁrst fraction was omitted
because it contained only buffer. The feed concentrations for mAb, CHOP and
gentamicin were 5.9 mg/ml, 2400 ng/ml (410 PPM) and 41 ng/ml (6.9 PPM)
respectively.
Conclusions
Overloading ion-exchange membrane adsorbers, a form
of frontal chromatography, was examined as the ﬁnal
step in the puriﬁcation of mAbs. We call this technique
overload chromatography. For three mAb feedstreams
previously puriﬁed over Protein A and ion-exchange column
chromatography, CHOP levels < 10 PPM and yields of
usually >99% were achieved with commercially available
membrane adsorbers Mustang® S and Q and Sartobind® S.
Results show that impurity clearance is consistent with
the factors that inﬂuence electrostatic adsorption. CHOP
puriﬁcation decreases with changes in pH and conductivity
that reduce net charge and increase ionic shielding. A
comparison between membrane brands shows similar
performance between the Mustang® and Sartobind®
membranes. Experimental results at ﬂow rates ranging from
333 to 2667 MV/h were consistent with the theory and
literatureclaimsthatmembraneperformanceisindependent
of ﬂow rate. Scale-up studies representing a 56-fold increase
in MV conﬁrmed that small, bench-top devices are capable
of predicting impurity clearance for much larger pleated
membranes.
The trace impurities found downstream of Protein
A are difﬁcult to remove and the preferred method of
clearance is often a combination of column chromatography
steps. Overload chromatography using membranes is
signiﬁcant because it provides an alternative approach for
dealingwithsomeoftheseproblematic species.Italsoopens
the door to further exploration for process streamlining,
perhaps via the direct linking of column and membrane
steps. Overload chromatography is an effective application
of a puriﬁcation technology that is uniquely advantageous
to membranes, as it lends itself to the large volume pools
typically encountered downstream of Protein A. Overall, the
results show that this approach can be used as a rapid, high-
yielding, ﬁnal puriﬁcation step for the production of mAbs.
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